Seelos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Notice of Effectiveness issued by the United States Securities and Exchange Commission (SEC) on March 15, 2024, at 4:00 P.M. The notice pertains to the Form S-1 filing, under the file number 333-276831. This development marks a key step for Seelos Therapeutics in its regulatory compliance and reporting process, allowing the company to move forward with its planned activities as outlined in the Form S-1 registration.

Seelos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Notice of Effectiveness issued by the United States Securities and Exchange Commission (SEC) on March 15, 2024, at 4:00 P.M. The notice pertains to the Form S-1 filing, under the file number 333-276831. This development marks a key step for Seelos Therapeutics in its regulatory compliance and reporting process, allowing the company to move forward with its planned activities as outlined in the Form S-1 registration.